Putting the guidance into context, in FY2017, the second-half NPAT was 66% of first-half NPAT.
This year - using the mid-point of the $1.55bn to $1.60bn NPAT guidance - they are effectively saying that second-half NPAT will be just 45% of first-half NPAT.
And, put another way, this guidance implies an 8% decline in JH2018 NPAT vs JH2017.
Which suggests:
1. there is something skewiff with the business,
2. there is going to be the mother of ramp-up sin R&D expenditure, or
3. the guidance is very conservative
I have a decidedly firm view of which one of those possibilities will turn out to be the case.
- Forums
- ASX - By Stock
- CSL
- Ann: Half Year Results Analyst Presentation
Ann: Half Year Results Analyst Presentation, page-11
-
- There are more pages in this discussion • 180 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$300.34 |
Change
-5.330(1.74%) |
Mkt cap ! $145.5B |
Open | High | Low | Value | Volume |
$301.50 | $305.00 | $300.24 | $129.7M | 430.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 218 | $300.34 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$300.41 | 8 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 112 | 300.510 |
5 | 47 | 300.500 |
4 | 46 | 300.490 |
1 | 20 | 300.480 |
3 | 44 | 300.470 |
Price($) | Vol. | No. |
---|---|---|
300.530 | 31 | 3 |
300.540 | 10 | 1 |
300.550 | 25 | 2 |
300.560 | 14 | 1 |
300.580 | 19 | 2 |
Last trade - 15.36pm 05/08/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |